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                                               Abstract 
   Thiourea-based Antithyroid drugs propylthiouracil (PTU), methimazole (MMI), and 
carbimazole (CBZ) may block the thyroid hormone biosynthesis whereas selenourea containing 
drugs reduce H2O2, which is required for oxidation of catalyst leads to decrease in thyroid 
hormone production. Thus,  new tris organo selone derivatives 3,3',3''-((2,4,6-trimethylbenzene-
1,3,5-triyl)tris(methylene))tris(1-(2,6-alkyl/aryl)-1H-imidazole-2(3H)-selenone) 4a-4f have been 
synthesized for the first time by the reaction of 1,1',1''-((2,4,6-trimethylbenzene-1,3,5-
triyl)tris(methylene))tris(3-alkyl/aryl-1H-imidazol-3-ium)bromide (1eq.), potassium carbonate 
(6eq.) and selenium powder (6eq.). These new molecules have been characterized by 
multinuclear NMR (
1
H NMR, 
13
C NMR, DEPT), FT-IR and UV-vis. studies. The 
1
H and 
13
C 
chemical shifts have been confirmed on the basis of correlation spectra e.g HSQC, HMBC. 
Photophysical properties have been derived from UV−vis. The molecular structures of 4a, 4b, 
4c, 4d and 4e have been determined by X-ray crystallography, which suggests that these 
compounds exist as zwitterions in which the selenium atom carries a large negative charge which 
enhances the nucleophilic activity of compounds. 
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Chapter 1 
 
1. Introduction 
 
      Organo Imidazoloselones have been subjected in various applications, such as in metalbased 
chemistry as a ligands,
[1]
 preparation of the metal selenides for the use of  materiel chemistry,
[2]
 and 
mainly used as antithyroid drugs
[3]
. 
 
1.1.   Thyroid hormone synthesis 
  
      Thyroid hormones play an important role in protein, fat, carbohydrate metabolism and cell growth [4]. 
Thyroid hormone secretes from thyroid gland are iodine-containing compounds that control the metabolic 
rate in every type of tissue the body. Thyroxine (T4), the main secretory hormone of the thyroid gland, is 
produced from thyroglobulin by thyroid peroxidase (TPO)/hydrogen peroxide/iodide system. Biologically 
active form of prohormone T4 is T3 which converts by a selenium-containing iodothyronine deiodinase 
9 
 
(ID-I), mostly exists in liver, kidney, thyroid and pituitary. This deiodination process is catalyzed by ID-I 
where the selenol (or selenolate) group of the enzyme (E-SeH or E-Se-) first reacts with thyroxine (T4) to 
form a selenenyl iodide (E-SeI) intermediate subsequently E-SeI completes the catalytic cycle and 
regenerates the selenol by intracellular cofactor (1,4-dithiothreitol (DTT, Cleland’s reagent) in vitro) 
(Scheme 1).
[4]
 
 
 
 
Autoantibodies causes activation of thyroid stimulating hormone (TSH) receptor leads to an 
overproduction of thyroid hormones. These antibodies stimulate ID-I and produce relatively more T3 
causing uncontrolled production of thyroid hormones leads to a condition called “hyperthyroidism” [5]. 
 
1.2.   Antithyroid drugs 
10 
 
 
      The overproduction of thyroid hormones can be controlled by specific inhibitors, called antithyroid 
drugs. These are mainly thiourea or selenourea based compounds. 
  
1.2.1.   Thiourea based antithyroid drugs 
[6]
 
 
 
 
      Detailed mechanistic study shows that thiourea-based antithyroid drugs may block the thyroid 
hormone biosynthesis in vivo by inhibiting TPO-catalyzed iodination of L-tyrosine in which it coordinate 
with TPO-Fe(III) center 
[7]
. Also it has been reported that the selenenyl iodide intermediate (E-SeI) reacts 
with PTU forming selenenyl sulfide destroying the catalytic enzyme at monodeiodination reaction, hence 
the conversion of T4 to T3 is blocked 
[8]
. 
 
 
 
1.2.2.   Selenourea based antithyroid drugs 
 
      In contrast to thiourea based drugs, it does not interfere with the native enzyme directly rather inhibits 
the enzyme activity by reducing the H2O2, which is required for the synthesis of thyroid hormone 
[9] 
thus it 
does not block the enzyme (Scheme 1). Selenium based antithyroid drugs exists in zwitterionic form 
where selenium carries the  negative charge this leads to higher activity of selenium based drugs than that 
of sulfur based 
[10] 
.  
 
1.2.2.1.    Mono selones 
[11]
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1.2.2.2.    Bis selones 
[12]
   
 
   
      'Hyperthyroidism', referred to an overactive thyroid, it is a condition where thyroid gland produces 
and secretes excessive amounts of thethyroid hormones. This is the opposite of hypothyroidism, in which 
production and secretion of T3 and/or T4 (i.e. thyroid hormones) reduced. Thyroid hormone is very 
important for our body, affecting metabolic rate nearly every type of tissue in the body.  
        If there is excess thyroid hormone, every function of our body tends to speed up as a result some of 
the symptoms i.e. nervousness, irritability, heart racing, anxiety and muscular weakness. 'Graves' disease 
is the most common in hyperthyroidism, the eyes may look enlarged because the eye muscles swell and 
push the eye forward. 
      Antithyroid drugs may inhibit the overproduction of thyroid hormones antithiroid drugs are mainly 
thiourea based or selenourea based compounds which prevent the conversion of thyroid hormone T4 to 
the active form T3. 
      Thiourea and selenourea derivatives inhibit thyroid hormone synthesis by completely different 
mechanism. Selenourea containing drugs reduce H2O2  which is required for oxidation of catalyst leads to 
12 
 
decrease in thyroid hormone production 
[10] 
 whereas Thiourea based drugs probably react with enzyme 
intermediates which can block hormone synthesis acting as irreversible inhibitor 
[13]
. 
      Selenium based antithyroid drugs exists in zwitterionic form where selenium carries the  negative 
charge this leads to higher activity of selenium based drugs than that of sulfur based 
[8]
.   
      Recently it has been seen that if we incorporate more than one selenium in one molecule it’s 
inhibition potency increases as an antithyroid drug 
[14]
.  
 
2.   Aim of work 
 
     Our aim is to synthesize and structurally characterize the antithyroid drug analogues of tris selones.  
 
21.   Target molecules  
Tris imidazole salts   Tris selenoureas  
 
3a  
 
4a 
 
3b  
 
4b 
13 
 
 
3c  
 
4c 
 
3d  
 
4d 
 
3e 
 
4e 
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3f 
 
4f 
 
Figure 4. Chemical structures of tris imidazole salts and tris selones 
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3.   Experimental section 
 
3.1.   General consideration 
 
      All manipulations were carried out under nitrogen using Schlenk vacuum line techniques. The 
solvents were purchased from commercial sources and purified according to standard procedures.
[15] 
 
[1,3,5-tris(bromomethyl)-2,4,6-trimethylbenzene mesityl tris methylene bromide] (1) was prepared as 
previously reported 
[16]
, N-Substituted imidazoles were synthesized from reported procedures 
[17]
. Starting 
materials were purchased from commercial sources and used without further purification. FTIR 
measurement (neat) was carried out on a Bruker Alpha-P Fourier transform spectrometer. The UV−vis 
spectra were measured on a T90+ UVvisble spectrophotometer. The fluorescent spectra were measured 
on a Fluoromax-4P TCSPC, Horiba Scientific spectrophotometer. High-resolution mass spectra (HR-MS) 
were recorded on an Agilent 6538 UHD Q-TOF. NMR spectra were recorded on Bruker Ultrashield-400 
MHz spectrometers at 25 
o
C unless otherwise stated. Chemical shifts are given relative to Me4Si and were 
referenced to the solvent resonances as internal standards. The crystal structures of 4a-4d and were 
measured on an Oxford Xcalibur 2 diffractometer. Data were collected at 150 K (for 4a, 4b) and 298 K 
(for 4c, and 4d). The structure of 4a-4e were solved by direct methods using the SIR-97 program
 [18]
 and 
refined with a full matrix least-squares method on F2 using the SHELXL-97 program
[19,20]
. CCDC 
000000-000000 contains the supplementary crystallographic data for this paper. These data can be 
obtained free of charge from the Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif or from the Cambridge Crystallographic Data Centre, 12 Union 
Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336 033; or e-mail: deposit@ccdc.cam.ac.uk. 
 
 
3.2.  Synthesis and characterization of 1,1',1''-((2,4,6-trimethylbenzene-1,3,5-
triyl)tris(methylene))tris(3-alkyl/aryl-1H-imidazol-3-ium) bromide (3) 
 
      To a stirred solution of 1,3,5-tris(bromomethyl)-2,4,6-trimethylbenzene in acetonitrile, 1-alkyl/aryl 
imidazole (4 eq) was added under nitrogen atmosphere, then the reaction mixture was stirred at 90 
o
C for 
3 days. The reaction progress was monitored by TLC. After 3days the precipitate formed in the reaction 
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mixture was filtered washed with diethylether then dried under high vacuum for 4 h to get desired 
compound in analytically pure-form. 
 
3b. White solid. Yield 76% (based on 1). M.P., 281-284 
o
C. FT-IR (neat, ῡ): 3393 (m), 3125 (w), 
3059 (m), 2978 (m), 1625 (w), 1550 (m), 1456 (w), 1431 (w), 1377 (w), 1330 (w), 1299 (w), 1269 (w), 
1177 (m), 1149 (s) cm
-1
.
 1
H NMR (CDCl3, 400 MHz): δ 10.10 (s, 3H, N-CH-N), 8.39 (s, 3H, Im-H), 7.31 
(s, 3H, Im-H), 5.82 (s, 6H, Mes-CH2-Im), 5.05-4.98 (m, 3H, N-CH(CH3)3), 2.36 (s, 9H, Ar-CH3), 1.53-
1.52 (d, 18H, JHH = 6.4 Hz, N-CH(CH3)3) ppm. 
13
C NMR δ 140.96 (ArC), 134.62 (N-CH-N), 129.17 
(ArC), 122.56 (Im-CH), 120.18 (Im-CH), 52.12 (N-CH(CH3)3), 47.75 (Mes-CH2-Im), 22.26 (N-
CH(CH3)3), 16.26 (Ar-CH3) ppm. HRMS (+ESI): calcd. for C30 H45 Br2 N6
+
 647.2072; found 647.2076. 
 
3c. Off white solid. Yield 88% (based on 1). M.P., above 300 
o
C. FT-IR (neat, ῡ): 3381 (w), 3095 
(w), 3070 (m), 3045 (m), 3002 (w), 2963 (m), 1647 (m), 1569 (m), 1545 (m), 1485 (w), 1335 (w), 1243 
(w), 1220 (w), 1159 (s) cm
-1
.
 1
H NMR (D2O, 400 MHz): δ 7.84-7.83 (d, 3H,
 
JHH = 2.4Hz, Im-H), 7.48-
7.47 (d, 3H, JHH = 2Hz, Im-H), 7.12-7.06 (q, 3H, N-CHCH2), 5.81-5.76 (dd, 3H,
 
JHH = 2.8Hz, N-CHCH2), 
5.64 (s, 6H, Mes-CH2-Im), 5.43-5.40 (dd, 3H,
 
JHH = 2.8Hz, N-CHCH2), 2.36 (s, 9H, Ar-CH3) ppm.
 13
C 
NMR (DMSO-d6, 100 MHz): δ 141.66 (ArC), 135.13 (N-CH-N), 128.86 (ArC), 128.77 (N-CHCH2), 
123.49 (Im-CH), 118.75 (Im-CH), 108.31 (N-CHCH2), 48.19 (Mes-CH2-Im), 16.47 (Ar-CH3) ppm. 
HRMS (+ESI): calcd. for C27 H33 Br2 N6
+
 599.1133; found 599.1134. 
 
 
3d. White solid. Yield 65% (based on 1). M.P., 135-137
o
C. FT-IR (neat, ῡ): 3399 (m), 3124 (w), 
3077 (w), 3014 (m), 2972 (w), 2926 (w), 1643 (w), 1574 (w), 1554 (s), 1495 (w), 1443 (w), 1417 (m), 
1384 (w), 1340 (w) cm
-1
. 
1
H NMR (D2O, 400 MHz): δ 7.53-7.52 (d, 3H,
 
JHH = 2Hz, Im-H), 7.43-7.42 (d, 
3H, JHH = 2.4Hz, Im-H), 6.06-5.98 (m, 3H, N-CH2CHCH2), 5.61 (s, 6H, Mes-CH2-Im),  5.42-5.28 (dd, 
6H,
 
JHH = 10.4Hz, N-CH2CHCH2), 2.33 (s, 9H, Ar-CH3) ppm.
 13
C NMR (D2O, 100 MHz): δ 141.62 (ArC), 
130.46 (N-CH2CHCH2), 129.05 (ArC), 122.86 (Im-CH), 122.06 (Im-CH), 120.74 (N-CH2CHCH2), 51.62 
(N-CH2CHCH2), 48.18 (Mes-CH2-Im), 15.74 (Ar-CH3) ppm. HRMS (+ESI): calcd. for C30 H39 Br3 N6 
720.0786; found 720.0805. 
 
 
3e. Off white solid. Yield 79% (based on 1). M.P., 241-243 
o
C.  FT-IR (neat, ῡ): 3383 (w), 3111 
(w), 3030 (w), 2961 (s), 2927 (m), 2868 (m), 2032 (w), 1623 (w), 1592 (w), 1540 (s), 1457 (s), 1418 (w), 
17 
 
1384 (w), 1364 (m) cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 10.57 (s, 3H, N-CH-N), 8.89 (s, 3H,  Im-H), 
7.49-7.45 (t, 3H, ArH), 7.25-7.23 (d, 6H, JHH = 8Hz, ArH), 7.06 (s, 3H, Im-H) 6.19 (s, 6H, Mes-CH2-Im), 
2.50 (s, 9H, Ar-CH3), 2.41-2.24 (m, 6H, Ar-CH(CH3)2),1.20-1.10(dd, 36H, JHH = 6.8Hz Ar-CH(CH3)2) 
ppm. 
13
C NMR (CDCl3, 100 MHz): δ 144.99 (ArC), 142.28 (ArC), 137.55 (ArC), 131.59 (N-CH-N), 
130.17 (ArC), 128.56 (ArC), 124.55 (ArC), 124.51 (Im-CH), 124.11 (Im-CH), 49.31 (Mes-CH2-Im), 
28.65 (Ar-CH(CH3)2), 24.48 (Ar-CH(CH3)2), 24.40 (Ar-CH(CH3)2), 17.43 (Ar-CH3) ppm.  
 
3f. Off white solid. Yield 75% (based on 1). M.P., 228-230 
o
C. FT-IR (neat, ῡ): 3397 (m), 3112 
(w), 2980 (w), 2922 (w), 2859 (w), 1622 (w), 1545 (s), 1474 (s), 1450 (m), 1384 (w), 1331 (w), 1181 (s), 
1100 (s), 1062 (m) cm
-1
. 
1
H NMR (D2O, 400 MHz): δ 7.74 (s, 3H, Im-H), 7.67 (s, 3H, Im-H), 7.44-7.40 (t, 
3H, ArH), 7.29-7.27 (d, 6H, JHH = 7.6Hz, ArH), 5.80 (s, 6H, Mes-CH2 -Im), 2.46 (s, 9H, Ar-CH3), 2.01 (s, 
18H, Ar-CH3) ppm. 
13
C NMR (D2O, 100 MHz): δ 141.77 (ArC), 134.72 (ArC), 133.13 (ArC), 130.86 
(ArC), 129.37 (ArC), 128.78 (ArC), 124.57 (Im-CH), 122.98 (Im-CH), 48.71 (Mes-CH2-Im), 16.55 (Ar-
CH3), 15.94 (Ar-CH3) ppm. HRMS (+ESI): calcd. for C45 H51 Br3 N6 912.1725; found 912.1722. 
 
3.3. Synthesis and characterization of 3,3',3''-((2,4,6-trimethylbenzene-1,3,5-
triyl)tris(methylene))tris(1-(2,6-alkyl/aryl)-1H-imidazole-2(3H)-selenone) (4) 
An oven dried schlenk tube was equipped with 1,1',1''-((2,4,6-trimethylbenzene-1,3,5-
triyl)tris(methylene))tris(3-alkyl/aryl-1H-imidazol-3-ium) bromide (1eq.), potassium carbonate (6eq.) and 
selenium powder (6eq.) under nitrogen atmosphere, subsequently MeOH was added then the reaction 
mixture was stirred for 36 h at 70 
o
C. The reaction progress was monitored by TLC. After 36 h reaction 
mixture was filtered through celite, washed with DCM (4 X 5 mL) then the combined organics were 
evaporated to get white solid followed by workup with DCM (2 X 20 mL ) and water (15 mL), gave 
analytically pure form of compound as white solid.The suitable crystals for X-ray analysis were grown in 
DCM/MeCN mixture (2:1) at 8 
o
C.   
 
4b. White solid. Yield 74% (based on 3). M.P., 236-238 
o
C. FT-IR (neat, ῡ): 3121 (w), 3082 (w), 
2971 (w), 2924 (m), 2854 (w), 1561 (w), 1459 (w), 1425 (m), 1407 (s), 1366 (m), 1331 (m), 1293 (w), 
1218 (m), 1196 (m) cm
-1
.
 1
H NMR (CDCl3, 400 MHz): δ 6.83-6.82 (d, 3H,
 
JHH = 2.4Hz, Im-H), 6.25-6.24 
(d, 3H,
 
JHH = 2.4Hz, Im-H), 5.29 (s, 6H, Mes-CH2-Im), 5.25-5.22 (m, 3H, N-CH-(CH3)3), 2.18 (s, 9H, Ar-
CH3), 1.39-1.38 (d, 18H, JHH = 6.8Hz, N-CH(CH3)3) ppm.
 13
C NMR (CDCl3, 100 MHz): δ 154.65 (C=Se), 
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139.95 (ArC), 131.22 (ArC), 116.95 (Im-CH), 115.04 (Im-CH), 50.88 (N-CH(CH3)2), 48.64 (Mes-CH2-
Im), 21.92 (N-CH(CH3)2), 16.81 (Ar-CH3) ppm.  
 
            4c. Brown solid. Yield 75% (based on 3). M.P., 212-214 
o
C. FT-IR (neat, ῡ): 3161 (w), 3130 (w), 
3086 (w), 2922 (w), 1692 (w), 1642 (s), 1564 (w), 1428 (s), 1325 (m), 1291 (w), 1225 (m), 1116 (w), 
1042 (w) cm
-1
.
 1
H NMR (CDCl3, 400 MHz): δ 7.69-7.63 (q, 3H, N-CHCH2), 7.08-7.07 (d, 3H,
 
JHH = 
2.4Hz, Im-H), 6.30-6.29 (d, 3H, JHH = 4Hz, Im-H),  5.30 (s, 6H, Mes-CH2-Im), 5.25-5.02 (dd, 6H,
 
JHH = 
7.2Hz, N-CHCH2), 2.23 (s, 9H, Ar-CH3) ppm.
 13
C NMR (CDCl3, 100 MHz): δ 157.53 (C=Se), 140.19 
(ArC), 131.59 (N-CHCH2), 131.02 (ArC) 117.69 (Im-CH), 114.96 (Im-CH), 102.45 (N-CHCH2), 48.60 
(Mes-CH2-Im), 16.96 (Ar-CH3) ppm.  
 
          4d. Off white solid. Yield 73% (based on 3). M.P., 234-236 
o
C. FT-IR (neat, ῡ): 3129 (w), 3087(w), 
2962 (w), 2917 (w), 1563 (w), 1440 (m), 1396 (s), 1327 (w), 1260 (m), 1235 (s), 1217 (s), 1178 (w), 1090 
(m), 1016 (s).
 1
H NMR (CDCl3, 400 MHz): δ 6.79-6.78 (d, 3H,
 
JHH = 2.4 Hz, Im-H), 6.25-6.24 (d, 3H,
 
JHH 
= 2.4 Hz, Im-H), 5.97-5.90 (m, 3H, N-CH2CHCH2), 5.31 (s, 6H, Mes-CH2-Im), 5.29-5.21 (m, 6H, N-
CH2CHCH2), 4.80-4.78 (d, 6H, JHH= 6.4 Hz, N-CH2CHCH2), 2.19 (s, 9H, Ar-CH3) ppm.
 13
C NMR 
(CDCl3, 100 MHz): δ 156.05 (C=Se), 139.98 (ArC), 131.42 (N-CH2CHCH2), 131.18 (ArC) 119.68 (N-
CH2CHCH2), 118.56 (Im-CH), 116.73 (Im-CH), 51.93 (N-CH2CHCH2), 48.98 (Mes-CH2-Im), 16.84 (Ar-
CH3) ppm.     
   
          4e. Off White solid. Yield 78% (based on 3). M.P., 122-124 
o
C. FT-IR (neat, ῡ): 3162 (w), 3135 
(w), 3073 (w), 2961 (m), 2924 (m), 2867 (m), 1560 (w), 1470 (m), 1416 (m), 1377 (m), 1349 (m), 1303 
(w), 1260 (s), 1216 (m), 1088 (m), 1020 (s) cm
-1
.
 1
H NMR (CDCl3, 400 MHz): δ 7.50-7.47 (t, 3H, ArH), 
7.31-7.29 (d, 6H, JHH = 7.6Hz, ArH), 6.83-6.82 (d, 3H,
 
JHH = 2Hz,  Im-H), 6.50-6.49 (d, 3H,
 
JHH = 2.4Hz, 
Im-H), 5.50 (s, 6H, Mes-CH2-Im), 2.50-2.47 (m, 6H, Ar-CH(CH3)2), 2.39 (s, 9H, Ar-CH3)  1.33-1.32 (d, 
18H,
 
JHH = 6.8Hz, Ar-CH(CH3)2), 1.11-1.09 (d, 18H,
 
JHH = 6.8Hz, Ar-CH(CH3)2) ppm. 
13
C NMR (CDCl3, 
100 MHz): δ 159.09 (C=Se), 146.09 (ArC), 139.87 (ArC), 133.83 (ArC), 131.91 (ArC), 130.34 (ArC), 
124.25 (ArC), 121.18 (Im-CH), 116.96 (Im-CH), 49.27 (Mes-CH2-Im), 29.65 (Ar-CH(CH3)2), 24.46 (Ar-
CH(CH3)2), 23.33 (Ar-CH(CH3)2), 16.95 (Ar-CH3) ppm.  
 
4f. Off White solid. Yield 65% (based on 3). M.P., 296-298 
o
C. FT-IR (neat, ῡ): 3149 (w), 3118 
(w), 3077 (w), 2963 (w), 2917 (w), 2855 (w), 1727 (w), 1553 (w), 1478 (m), 1443 (w), 1416 (w), 1375 
(s), 1332 (m), 1260 (w), 1120 (m) cm
-1
. 
1
H NMR (CDCl3, 400 MHz): δ 7.32-7.28 (t, 3H, ArH), 7.20-7.18 
(d, 6H, JHH = 7.6Hz, ArH), 6.80-6.79 (d, 3H,
 
JHH = 2.4Hz, Im-H), 6.50-6.49 (d, 3H,
 
JHH  = 2Hz, Im-H), 
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5.46 (s, 6H, Mes-CH2-Im), 2.36 (s, 9H, Ar-CH3), 2.07 (s, 18H, Ar-CH3) ppm. 
13
C NMR (CDCl3, 100 
MHz): δ 156.84 (C=Se), 139.90 (ArC), 136.43 (ArC), 135.73 (ArC), 131.71 (ArC), 129.60 (ArC), 128.51 
(ArC), 119.62 (Im-CH), 117.48 (Im-CH), 49.14 (Mes-CH2-Im), 18.15 (Ar-CH3), 16.96 (Ar-CH3) ppm.  
 
3.4.   Preparation of solution of compounds for fluorescence spectroscopy 
         All the tris imidazole salts [1,1',1''-((2,4,6-trimethylbenzene-1,3,5-triyl)tris(methylene))tris(3-
alkyl/aryl-1H-imidazol-3-ium) bromide] (3) (1.87 10-5 M) were dissolved in 25 mL DMSO. So that 
concentration of all the solutions was remain same. 
Tris selones [3,3',3''-((2,4,6-trimethylbenzene-1,3,5-triyl)tris(methylene))tris(1-(2,6-alkyl/aryl)-1H-
imidazole-2(3H)-selenone)] (4) were also dissolved in same concentration (1.87  10-5 M) in 25 mL 
DMSO keeping same concentration. 
3.5.   Preparation of solution of compounds for U.V-Vis spectroscopy 
       Solutions were prepared same as in the case of fluorescence for tris imidazole salts and tris selones. 
3.6.   Preparation of solutions for 
1
H NMR study of compounds 
      0.015g of each tris selones was taken in a thoroughly cleaned NMR tube and was dissolved in 0.5 mL 
of CDCl3 at room temperature. For tris imidazole salts the amount of compound has taken for 
1
H NMR is 
same but solvent varies for various compounds e.g D2O has been used for compounds 3a, 3c, 3d, 3f and 
CDCl3 for 3b, 3e. 
3.7. Preparation of solutions for 
13
C NMR, DEPT, HSQC, HMBC study of compounds 
      0.025g of tris selone compounds have taken in a cleaned NMR tube and were dissolved in 0.5 mL of 
CDCl3 at room temperature. Same amount of tris imidazole salts were taken but with various solvents. 
D2O was used for 3a, 3d, 3f, CDCl3 for 3e and DMSO-d6 for 3b, 3c.  
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4.   Scheme 
4.1.  Synthesis of 1,1',1''-((2,4,6-trimethylbenzene-1,3,5-triyl)tris(methylene))tris(3-
alkyl/aryl-1H-imidazol-3-ium) bromide (3) 
 
 
4.2.   Synthesis of 3,3',3''-((2,4,6-trimethylbenzene-1,3,5-triyl)tris(methylene))tris(1-(2,6-
alkyl/aryl)-1H-imidazole-2(3H)-selenone) (4) 
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5.   Results and discussion 
5.1.   Synthesis and characterization of (3) 
      Compounds 3a-3f were synthesized from the reaction between 1,3,5-tris(bromomethyl)-2,4,6-
trimethylbenzene and 4 equivalence of N-substituted imidazole in acetonitrile at 90 
o
C for three days 
afford a large precipitate, which was purified by washing with diethyl ether or acetone to get analytical 
pure compounds with 65%, 76%, 88%, 65%, 79%, 75% yields respectively. And the product formation 
was confirmed by NMR (
1
H, 
13
C and DEPT) and further these were characterized by IR and Uv-visible 
technique. 3b-3f were stable solids at normal atmosphere. 3a is hygroscopic white solid.  
 
 
 
5.2.   Synthesis and characterization of (4) 
 
      Compounds 4a-4f were synthesized from the reaction between 3a-3f ,6 equivalence potassium 
carbonate and 6 equivalence of Se in methanol at 70 
o
C for two days afford a large precipitate, which was 
purified by washing with methanol to get analytical pure compounds with 60%, 74%, 75%, 73%, 78%, 
65% yields respectively. And the product formation was confirmed by NMR (
1
H, 
13
C and DEPT) and 
further these were characterized by IR and Uv-visible technique. 4a-4f were stable solids at normal 
atmosphere. 
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5.3.   FT-IR Studies 
  
      The IR spectra exhibit intense N–C–N and C=Se stretching at about a range 1540-1554, 1110-1200 
cm–1 for 3a-3f and 4a-4f respectively. 
 
5.4.   NMR Studies  
 
      The NMR spectra for the salts and selones were recorded in different deuterated solvents {CDCl3 (3b, 
3e, 4a-4f), D2O (3a, 3c, 3d, 3f)}, at room temperature. 
1
H and 
13
C chemical shifts were made on the basis 
of 2D (HSQC and HMBC) NMR experiments. Due to the low solubility of  3b, 3c in organic solvents, 
their 
13
C NMR spectra were recorded in DMSO-d6. 
1
H NMR for selones in CDCl3 spectrum exhibits in 
the aliphatic region singlet resonances for Ar–CH3 (2.12-2.39 ppm) and Mes-CH2-Im (5.17-5.50 ppm) 
groups (Figure 6). For the corresponding salts the resonances are found in the following ranges: 2.33-
2.50 ppm for Ar–CH3 and 5.59-6.19 ppm for Mes-CH2-Im (Figure 5) For compounds 3b and 3e in 
CDCl3, 
1
H NMR signals are downfield shifted δ 10.10, 10.57 ppm for N-CH-N proton whereas in 
compounds 4a-4f this downfield proton’s peak disappears. N-CH-N proton for Compounds 3a, 3c, 3d, 3f 
in D2O also did not give any peak due to D2O exchange. The –CH–CH– protons of the imidazole rings 
appear in the range 6.24-7.30, 7.06-8.89 ppm in the salts and in the selones, a downfield shift is observed.
 
13
C NMR spectrum of 3a-3f and 4a-4f exhibits the following pattern ranges of the values 15.74-17.43 and 
16.81-16.96 ppm for Ar–CH3 and 47.75-49.31, 48.60-49.27 ppm for Mes-CH2-Im respectively. In 
13
C 
NMR the N-CH-N carbons of 3a-3f are in a range of δ 131.59-134.62 ppm  
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(Figure 7) and Compounds 4a-4f show a singlet in a range of δ 154.65-159.09 ppm (Figure 8) which 
prove the existence of C=Se group 
[21]
. Compounds 3d and 3f did not show any peak in 
13
C NMR.  
 
 
 
 
 
 
                                       
 
 
 
 
Figure 5. 
1
H NMR spectra of 3a-3f 
at RT. 
 
Figure 6. 
1
H NMR spectra of 4a-4f 
at RT. 
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Figure 9. 
1
H NMR spectrum (400 MHz, CDCl3, RT) of 4b. 
Figure 7. 
13
C NMR spectra of 3a-3f at 
RT. 
 
Figure 8. 
13
C NMR spectra of 4a-4f at 
RT. 
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Figure 10. 
13
C NMR spectrum (400 MHz, CDCl3, RT) of 4b. 
 
 
Figure 11. DEPT spectrum (400 MHz, CDCl3, RT) of 4b. 
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2D NMR Spectrums  
   
                       Figure 12. HSQC (400 MHz, CDCl3, RT) of 4b. 
 
                         Figure 13. HMBC (400 MHz, CDCl3, RT) of 4b. 
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5.5.   U-vis Studies                                                              
 
      In order to understand electronic-structure property relationships for 4a-4f, solution phase study 
ultraviolet−visible excitation were performed in DMSO at room temperature with concentration 1.87 10-
5
 M displayed a nearly comparable absorption maxima pattern at 258, 259, 279, 281, 284, 286 nm with an 
absorbance maxima value 0.5106 to 0.6443. Absorbance studies on the tris selone series are compiled 
graphically in (Figure 14), and selected optical properties are also shown in (Table 1). Compounds 4b-4f 
produce two absorption peaks one is sharp and other is comparably broad, are in a range of 257-259 nm 
and 279-314 nm, distinct absorptions due to π−π* transitions from their structural contributions. The π to 
π* transition intensity is decreased in the order of 4f, 4a, 4b, 4d, 4e, 4c. 
 
 
Figure 14. Solution absorbance spectra of compounds 4a−4f (1.87 10-5 M) in DMSO 
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Entry 4a 4b 4c 4d 4e 4f 
λmax 
(nm) 
279 259 258 281 286 284 
log(ε)a 4.5324 4.5099 4.4362 4.5008 4.4711 4.5372 
Abs. 0.6372 0.6050 0.5106 0.5925 0.5533 0.6443 
Table-1. 
a
.ε reported in L mol−1 cm-1 
 
5.6.   Crystal Structures 
 
Figure 15. Structure of the asymmetric unit of 4a. 
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Figure 16. Molecular packing orientation of 4a (View along c axis). 
 
Figure 17. Structure of the asymmetric unit of 4b. 
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Figure 18. Molecular packing orientation of 4b (View along b axis).
 
  
Figure 19. Structure of the asymmetric unit of 4c. 
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Figure 20. Molecular packing orientation of 4c (View along c axis). 
 
Figure 21. Structure of the asymmetric unit of 4d.
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Figure 22. Molecular packing orientation of 4d (View along c axis).
 
 
Figure 23. Structure of the asymmetric unit of 4e. 
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Figure 24. Molecular packing orientation of 4e (View along c axis). 
 
 
Figure 25. Structure of the asymmetric unit of 4f. 
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Figure 26. Molecular packing orientation of 4f (View along a axis).
 
 
 
      The crystal structure of the tris selone and the complexes 4a, 4b, 4c, 4d and 4e have been determined 
by single-crystal X-ray diffraction studies and selected bond lengths are presented in Tables 2 and 3 
respectively.
 
 
      The two imidazoline-2-selone in compounds 4a are oriented in below and another one is in the above 
(Figure 15). Compound 4b has the same selenourea moitie orientation as in compound 4a i.e. two moities 
are in downward and other is in upward (Figure 17). In compound 4c all the selenourea moities are 
aligned in the same upward direction (Figure 19). Next compound 4d also has two selone group in below 
and third one in above (Figure 21). In case of compound 4e two imidazole rings are facing in one side 
and another in opposite side (Figure 23).Compound 4f got two selone group in the above of the plane of 
mesitylene and other one is in below (Figure 25). 
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      To understand the nature of C–Se bonds in these selone derivatives, bond lengths of C–S/C–Se has to 
be compared with that of the previously reported thiourea compounds and our present compounds. Based 
on X-ray diffraction studies, average bond length of C–S is 1.683A˚ which is quite shorter than the C–S 
single bond (1.810 A˚) and slightly longer than the C–S double bond (1.610 A˚)[22] whereas the C–Se 
bond lengths in the tris selone compounds 4a (1.844 A˚), 4b (1.850 A˚), 4c (1.827 A˚), 4d (1.827 A˚ ) and 
4e (1.821 A˚), 4f (1.832 A˚) (Table-2) are nearly comparable to the true C–Se single bond (1.940A˚). So 
we can conclude that the C–S bond in thione has more of double bond character than C–Se in selone, thus 
selones exist in it’s zwitterionic form where carbon has positive and selenium has a negative charge. The 
negative charge on selenium increases it’s nucleophilic activity [23]. 
 
 
Compounds Se–C (Å) Avg. N–C (Å) Angel/⁰ N–C–N 
4a 1.844 1.354 104.9 
4b 1.850 1.339 107.16 
4c 1.827 1.362 105.79 
4d 1.827 1.353 105.79 
4e 1.821 2.058 104.23 
4f 1.832 1.374 105.44 
Table-2. Selected bond lengths and angles of 4a, 4b, 4c, 4d, 4e and 4f. 
6.  Conclusion 
       Since, the di-selenourea can inhibit PN-mediated nitration of BSA much actively than that of the 
mono-selenoureas, we have incorporated the three active selenium sites in a molecule. Thus, we have 
successfully synthesized a series of mesityl tris selone compounds 4a-4f in highly pure form. The yield of 
4a-4f were excellent. Compounds 4a-4f are stable toward moisture and air. The formation of 4a-4f were 
confirmed by multinuclear 1D and 2D NMR studies like 
1
H NMR, 
13
C NMR, DEPT, HSQC, HMBC. 
These new molecules were further studied by FT-IR and UV-vis spectroscopies. For the first time, the 
solid state structures of tris selone compounds, 4a-4f were further confirmed by single crystal X-ray 
technique. 
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